Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderate...
Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Objective:
To determine and compare the cost utilities of the tumour necrosis factor (TNF) antagonists adalimumab and infliximab as maintenance therapies for patients in the US with moderately to severely active Crohn’s disease.
Methods:
Maintenance regimens of adalimumab (40 mg every other week) and infliximab (5 mg/kg) were compared usin...
Alternative Titles
Full title
Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_222285291
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_222285291
Other Identifiers
ISSN
1170-7690
E-ISSN
1179-2027
DOI
10.2165/11312710-000000000-00000
